Clinical trial
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
NCT02917629 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2018
- Completion date
- August 28, 2019
- Enrollment
- 6 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
oral cavity neoplasm, oropharyngeal neoplasm, stage 0 oral cavity squamous cell carcinoma american joint committee on cancer (ajcc) v6 and v7, stage 0 oropharyngeal squamous cell carcinoma ajcc v6 and v7, stage i oral cavity squamous cell carcinoma ajcc v6 and v7, stage i oropharyngeal squamous cell carcinoma ajcc v6 and v7, stage ii oral cavity squamous cell carcinoma ajcc v6 and v7, stage ii oropharyngeal squamous cell carcinoma ajcc v6 and v7, stage iii oral cavity squamous cell carcinoma ajcc v6 and v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iva oral cavity squamous cell carcinoma ajcc v6 and v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7, stage ivb oral cavity squamous cell carcinoma ajcc v6 and v7, stage ivb oropharyngeal squamous cell carcinoma ajcc v7